ImmuCell Corporation Statistics
Share Statistics
ImmuCell Corporation has 8.91M shares outstanding. The number of shares has increased by 14.98% in one year.
| Shares Outstanding | 8.91M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 13.77% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.74M |
| Failed to Deliver (FTD) Shares | 298 |
| FTD / Avg. Volume | 1.86% |
Short Selling Information
The latest short interest is 4.01K, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 4.01K |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.07% |
| Short Ratio (days to cover) | 0.23 |
Valuation Ratios
The PE ratio is -6.79 and the forward PE ratio is -33.18.
| PE Ratio | -6.79 |
| Forward PE | -33.18 |
| PS Ratio | 2.24 |
| Forward PS | null |
| PB Ratio | 1.57 |
| P/FCF Ratio | -5.97 |
| PEG Ratio | n/a |
Enterprise Valuation
ImmuCell Corporation has an Enterprise Value (EV) of 56.13M.
| EV / Earnings | -9.72 |
| EV / Sales | 3.21 |
| EV / EBITDA | -22.41 |
| EV / EBIT | -9.76 |
| EV / FCF | -8.55 |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.48.
| Current Ratio | 2.73 |
| Quick Ratio | 0.87 |
| Debt / Equity | 0.48 |
| Total Debt / Capitalization | 32.38 |
| Cash Flow / Debt | -0.39 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.23% and return on capital (ROIC) is -13.8%.
| Return on Equity (ROE) | -0.23% |
| Return on Assets (ROA) | -0.13% |
| Return on Capital (ROIC) | -13.8% |
| Revenue Per Employee | 232.96K |
| Profits Per Employee | -76.99K |
| Employee Count | 75 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 1.67 |
Taxes
| Income Tax | 4.63K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -4.55% in the last 52 weeks. The beta is 0.57, so ImmuCell Corporation's price volatility has been higher than the market average.
| Beta | 0.57 |
| 52-Week Price Change | -4.55% |
| 50-Day Moving Average | 4.35 |
| 200-Day Moving Average | 4.27 |
| Relative Strength Index (RSI) | 57.38 |
| Average Volume (20 Days) | 16.01K |
Income Statement
In the last 12 months, ImmuCell Corporation had revenue of 17.47M and earned -5.77M in profits. Earnings per share was -0.75.
| Revenue | 17.47M |
| Gross Profit | 4.40M |
| Operating Income | -5.75M |
| Net Income | -5.77M |
| EBITDA | -2.50M |
| EBIT | -5.75M |
| Earnings Per Share (EPS) | -0.75 |
Balance Sheet
The company has 978.74K in cash and 16.69M in debt, giving a net cash position of -15.71M.
| Cash & Cash Equivalents | 978.74K |
| Total Debt | 16.69M |
| Net Cash | -15.71M |
| Retained Earnings | -12.01M |
| Total Assets | 44.45M |
| Working Capital | 9.42M |
Cash Flow
In the last 12 months, operating cash flow was -4.67M and capital expenditures -1.89M, giving a free cash flow of -6.57M.
| Operating Cash Flow | -4.67M |
| Capital Expenditures | -1.89M |
| Free Cash Flow | -6.57M |
| FCF Per Share | -0.85 |
Margins
Gross margin is 25.16%, with operating and profit margins of -32.9% and -33.05%.
| Gross Margin | 25.16% |
| Operating Margin | -32.9% |
| Pretax Margin | -33.02% |
| Profit Margin | -33.05% |
| EBITDA Margin | -14.33% |
| EBIT Margin | -32.9% |
| FCF Margin | -37.59% |
Dividends & Yields
ICCC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.91% |
| FCF Yield | -14.64% |
Analyst Forecast
Currently there are no analyst rating for ICCC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 25, 1990. It was a backward split with a ratio of 1:100.
| Last Split Date | Jul 25, 1990 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | 94.14 |
| Piotroski F-Score | 4 |